Arctic Bioscience – funded to cash positive
· Arctic Bioscience is now funded through a NOK 30 million loan facility. · Strong 30% y/y growth in sales revenues in 2024 and prospects of continued strong growth in coming years. · Psoriasis drug candidate HRO350 on track for 12 months readout end of Q1.Reference is made to the stock exchange notice 29[th] October 2024 on Q3 2024 Operational update. The Company announced working on various financing opportunities, where a liquidity contribution of around NOK 30 million was estimated to bring the Company into a positive cash flow position. New funding of NOK 30 million is now